share_log

Piper Sandler Downgrades Fulgent Genetics to Neutral, Lowers Price Target to $40

Piper Sandler Downgrades Fulgent Genetics to Neutral, Lowers Price Target to $40

派珀·桑德勒将 Fulgent Genetics 评级下调至中性,将目标股价下调至40美元
Benzinga Real-time News ·  2022/12/08 05:14

Piper Sandler analyst David Westenberg downgrades Fulgent Genetics (NASDAQ:FLGT) from Overweight to Neutral and lowers the price target from $65 to $40.

派珀·桑德勒分析师David·韦斯滕伯格将富金特遗传公司(纳斯达克股票代码:FLGT)的评级从增持下调至中性,并将目标价从65美元下调至40美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发